SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Germany · Delayed Price · Currency is EUR 23.05
-0.25 (-1.07%)
At close: Sep 4, 2026
ETR:1SXP Income Statement
Financials in millions EUR. Fiscal year is October - September.
Millions EUR. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
| 1,017 | 986.21 | 957.09 | 898.6 | 821.14 | 648.67 | |
Revenue Growth | 4.15% | 3.04% | 6.51% | 9.43% | 26.59% | 11.03% |
Cost of Revenue | 699.9 | 653.75 | 634.48 | 582.11 | 524.51 | 422.5 |
Gross Profit | 316.91 | 332.46 | 322.61 | 316.49 | 296.64 | 226.17 |
Selling, General & Admin | 134.43 | 130.62 | 125.18 | 122.68 | 110.78 | 92.5 |
Research & Development | 26.08 | 27.92 | 24.25 | 26.82 | 23.53 | 22.29 |
Other Operating Expenses | -10.83 | -11.81 | -15.67 | -4.23 | -5.68 | -3.12 |
Operating Expenses | 149.68 | 146.73 | 133.77 | 145.28 | 128.63 | 111.67 |
Operating Income | 167.23 | 185.74 | 188.84 | 171.21 | 168.01 | 114.5 |
Interest Expense | -16.59 | -19.26 | -12.78 | -6.66 | -2.11 | -1.19 |
Interest & Investment Income | 8.15 | 7.95 | 5.96 | 5.23 | 2.14 | 0.56 |
Earnings From Equity Investments | 16.18 | 13.88 | 12.49 | 11.74 | 12.99 | 13.7 |
Currency Exchange Gain (Loss) | -0.29 | -0.29 | -11.09 | 2.71 | -7.03 | -1.45 |
Other Non Operating Income (Expenses) | -0.47 | -1 | -1.08 | -4.55 | -5.54 | -3.26 |
EBT Excluding Unusual Items | 174.2 | 187.02 | 182.35 | 179.68 | 168.46 | 122.87 |
Merger & Restructuring Charges | - | - | - | - | -11.78 | - |
Gain (Loss) on Sale of Assets | 0.33 | 0.33 | 0.59 | 0.39 | 1.51 | 0.3 |
Asset Writedown | - | - | - | 5.2 | - | - |
Pretax Income | 174.94 | 187.76 | 183.97 | 185.8 | 158.29 | 123.28 |
Income Tax Expense | 38.22 | 40.77 | 33.63 | 33.87 | 32.44 | 22.12 |
Earnings From Continuing Operations | 136.72 | 146.98 | 150.35 | 151.93 | 125.85 | 101.17 |
Minority Interest in Earnings | -0.5 | -0.53 | -0.66 | -0.09 | -0.47 | -0.41 |
Net Income | 136.22 | 146.45 | 149.69 | 151.84 | 125.38 | 100.75 |
Net Income to Common | 136.22 | 146.45 | 149.69 | 151.84 | 125.38 | 100.75 |
Net Income Growth | -7.48% | -2.16% | -1.42% | 21.11% | 24.44% | 30.04% |
Shares Outstanding (Basic) | 151 | 151 | 151 | 151 | 151 | 151 |
Shares Outstanding (Diluted) | 151 | 151 | 151 | 151 | 151 | 151 |
Shares Change | -0.12% | - | - | - | - | - |
EPS (Basic) | 0.90 | 0.97 | 0.99 | 1.01 | 0.83 | 0.67 |
EPS (Diluted) | 0.90 | 0.97 | 0.99 | 1.01 | 0.83 | 0.67 |
EPS Growth | -7.25% | -2.02% | -1.80% | 21.46% | 24.08% | 31.17% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Free Cash Flow | 55.18 | 35.6 | 79.69 | 6.19 | 30.11 | 34.14 |
Free Cash Flow Per Share | 0.36 | 0.24 | 0.53 | 0.04 | 0.20 | 0.23 |
Dividend Per Share | 0.180 | 0.180 | 0.160 | 0.150 | 0.125 | - |
Dividend Growth | 12.50% | 12.50% | 6.67% | 20.00% | - | - |
Gross Margin | 31.17% | 33.71% | 33.71% | 35.22% | 36.13% | 34.87% |
Operating Margin | 16.45% | 18.83% | 19.73% | 19.05% | 20.46% | 17.65% |
Profit Margin | 13.40% | 14.85% | 15.64% | 16.90% | 15.27% | 15.53% |
Free Cash Flow Margin | 5.43% | 3.61% | 8.33% | 0.69% | 3.67% | 5.26% |
EBITDA | 249.3 | 259.64 | 249 | 217.5 | 211.8 | 150.94 |
EBITDA Margin | 24.52% | 26.33% | 26.02% | 24.20% | 25.79% | 23.27% |
D&A For EBITDA | 82.07 | 73.91 | 60.16 | 46.29 | 43.79 | 36.44 |
EBIT | 167.23 | 185.74 | 188.84 | 171.21 | 168.01 | 114.5 |
EBIT Margin | 16.45% | 18.83% | 19.73% | 19.05% | 20.46% | 17.65% |
Effective Tax Rate | 21.85% | 21.72% | 18.28% | 18.23% | 20.49% | 17.94% |